Skip to main content
Caplight Logo









NanoVax Therapeutics

NanoVax Therapeutics

Private
Amherst, MassachusettsHealthcare & Life Scienceshttps://nanovaxtherapeutics.com/

Company Overview

NanoVax Therapeutics is a biotechnology company developing next-generation nanoparticle-based cancer vaccines designed to prime and direct tumor-specific T-cell responses.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Data as a Service, Services & Consulting

AI Layer

Non-AI

Keywords

lipid nanoparticleLNPcancer vaccineimmunotherapydrug deliveryoncologytherapeutic vaccinepersonalized medicinebiotech startuppreclinical researchdrug licensingnext-gen vaccines

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

NanoVax Therapeutics Comparables

Compare NanoVax Therapeutics with similar companies based on industry and business-model similarity.

NanoVax Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Foxcroft Therapeutics, Inc.
91%
Hopewell Therapeutics
79%
Bristol Myers Squibb
74%

NanoVax Therapeutics Funding Rounds

Historical fundraising activity

View Full Funding History

Access detailed round history, amounts raised, valuations, and investors.

Key People

Founding team and executive leadership

Griffin Kane

Co-Founder CEO

Founding Team

NanoVax Therapeutics Filings

Explore SEC and related filing metadata, where available.

NanoVax Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about NanoVax Therapeutics's valuation, stock price, and market status.

Is NanoVax Therapeutics a public or private company?

NanoVax Therapeutics is a private company.

What is the current stock price of NanoVax Therapeutics?

NanoVax Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is NanoVax Therapeutics worth (valuation)?

Valuation information for NanoVax Therapeutics is not publicly available.

Can I buy NanoVax Therapeutics stock?

NanoVax Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was NanoVax Therapeutics's last funding round?

Funding round information for NanoVax Therapeutics is not publicly available.

Who are the main investors in NanoVax Therapeutics?

Investor information for NanoVax Therapeutics is not publicly disclosed.

Will NanoVax Therapeutics IPO soon?

No public IPO plans have been announced for NanoVax Therapeutics.

How can I track NanoVax Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor NanoVax Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersAmherst, Massachusetts
Employee Range1
Year Founded2025
Last Funding—

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?